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CancerSmall heterodimer partner (SHP, NR0B2) is a unique member of the nuclear receptor (NR) superfamily that
contains the dimerization and ligand-binding domain found in other family members, but lacks the conserved
DNA-binding domain. The ability of SHP to bind directly tomultiple NRs is crucial for its physiological function
as a transcriptional inhibitor of gene expression. A wide variety of interacting partners for SHP have been
identiﬁed, indicating the potential for SHP to regulate an array of genes in different biological pathways. In
this review, we summarize studies concerning the structure and target genes of SHP and discuss recent
progress in understanding the function of SHP in bile acid, cholesterol, triglyceride, glucose, and drug
metabolism. In addition, we review the regulatory role of SHP in microRNA (miRNA) regulation, liver ﬁbrosis
and cancer progression. The fact that SHP controls a complex set of genes in multiple metabolic pathways
suggests the intriguing possibility of developing new therapeutics for metabolic diseases, including fatty liver,
dyslipidemia and obesity, by regulating SHP with small molecules. To achieve this goal, more progress
regarding SHP ligands and protein structure will be required. Besides its metabolic regulatory function,
studies by us and other groups provide strong evidence that SHP plays a critical role in the development of
cancer, particularly liver and breast cancer. An increased understanding of the fundamental mechanisms by
which SHP regulates the development of cancers will be critical in applying knowledge of SHP in diagnostic,
therapeutic or preventive strategies for speciﬁc cancers. This article is part of a Special Issue entitled:
Translating nuclear receptors from health to disease.slating nuclear receptors from
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Nuclear receptors (NRs) are a unique family of transcription factors
(TFs) that exert critical roles in almost all aspects of mammalian
development, metabolism and physiology [1]. Many NRs directly
activate or repress their target genes by binding to the hormone
response elements (HREs) in promoters or enhancer regions via DNA-
binding domains (DBDs). In addition, NRs can bind speciﬁc activating
molecules through ligand-binding domains (LBDs), and interact with
other coactivators and corepressors to mediate transcriptional regula-
tion. Dysfunction of nuclear receptor signaling leads to awide spectra of
proliferative, reproductive, and metabolic diseases, including obesity,
diabetes, and cancers.
Small heterodimer partner (SHP, NR0B2) is a unique NR which is
distinct fromconventional NRs in both structure and function [2]. Due to
its lack of identiﬁed endogenous ligands, SHP belongs to the “orphan”
subfamily. SHPexecutes its regulatory function throughprotein–protein
interactions with other NRs and TFs. In this review, we have attempted
to survey all currently available published literatures concerning thestructure and target genes of SHP, and discuss recent progress in
understanding the function of SHP in regulating bile acid synthesis,
cholesterol, lipid and glucosemetabolism, aswell as its role inmicroRNA
regulation and cancer development.
2. SHP gene structure and genetic variations in humans
SHP was originally cloned in 1996, based on its interaction in yeast
two-hybrid assays with several conventional and orphan members of
the receptor superfamily, including the constitutive androstane recep-
tor, retinoid receptors, thyroid hormone receptor, and orphan receptor
MB67 [2]. The genomic structure of SHP consists of two exons
interrupted by a single intron spanning approximately 1.8 kilobases in
humansand1.2 kilobases inmouse.Genomic Southernblot analysis and
ﬂuorescence in situ hybridization of human metaphase chromosomes
indicated that the SHPgene is locatedathumanchromosome1p36.1 [3].
Mouse and rat SHP reside in chromosome 4 and 5, respectively.
SHP is an orphan member of the nuclear hormone receptor
superfamily that contains the dimerization and ligand-binding domain
(LBD) found in other family members, but lacks the conserved DNA-
binding domain (DBD) [2]. The ability of SHP to bind directly to a
variety of NRs is crucial for its physiological function as a transcrip-
tional inhibitor of gene expression. SHPbinds to theAF-2domain (theC-
terminal transcription activation domain located within the LBD of
ligand-regulated and constitutive active NRs) through two functional
Fig. 1. Domain structure of the orphan nuclear receptor SHP. Classical nuclear receptor (NR) contains ﬁve major functional domains: the N-terminal ligand-independent
transactivation domain (A/B domain), the DNA-binding domain (DBD or C domain), hinge region (D domain), the C-terminal ligand-binding domain (LBD or E domain), and the
ligand-dependent transactivation domain (AF2 or F domain). Compared to the classical NRs, SHP contains the dimerization and LBD domain, but lacks the conserved DBD. SHP
represses the transcriptional activities of its targets gene by utilizing two functional LXXLL-related motifs (also called NR-boxes) which are located in the putative N-terminal helix 1
of the LBD and in the C- terminal region of helix 5.
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putative N-terminal helix 1 of the LBD and in the C-terminal region of
helix 5 (Fig. 1) [4].
SHPgene is expressed anddetected in a variety of tissues. Expression
proﬁling of the 49 known NR mRNAs in 39 tissues from two strains of
mice, 12931/SvJ and C57/BL6, showed that SHP is predominantly
expressed in the gallbladder and liver, and at lower levels in the
brainstem, cerebellum, adrenal, pancreas, stomach, duodenum, jeju-
num, ileum, colon, kidney, ovary, testis, and heart [5]. In humans, SHP
mRNA is detected in the liver, heart, pancreas, kidney, spleen, small
intestine, adrenal gland and stomach [3,6,7]. Genetic variations
including deletions, insertions, repetitive elements, single nucleotide
polymorphisms (SNP), and large chromosomal rearrangements can
cause diseases by affecting important biological processes. To date, theTable 1
Summary of the mutations identiﬁed in the human SHP gene (NR0B2).
Region Nucleotide change Protein change (codon affected) Protein activ
Promoter Pro -423CNT Unknown
Pro -394CNT Unknown
Pro -195delCTGA Unknown
Exon1 c.65CNT p.Y22Y Normal
c.100CNT p.R34X Reduced
c.100CNG p.R34G Normal
p.R36C Unknown
c.112CNT p.R38C Normal
c.113GNA p.R38H Normal
c.134GNC p.R45P Normal
c.157_166del p.His53AlafsX50 Reduced
c.160CNT p.R54C Reduced
c.169CNT p.R57W Reduced
c.278GNA p.G93D Reduced
c.292_300delinsAC p.L98fsdel9insAC Reduced
c.314TNG p.V105G Reduced
c.339GNA p.P133P Normal
c.415CNA p.P139H Normal
c.510ANT p.K170N Reduced
c.512GNC p.G171A Normal
c.532GNA p.D178N Normal
Intron Intron1265TNA Unknown
Exon2 c.566GNA p.G189E Reduced
c.583GNT p.A195S Reduced
c.618GNA p.W206X Reduced
c.637CNT p.R213C Reduced
c.647GNA p.R216H Normal
c.903CNT Unknown
3′ UTR 3′UTR101CNG Unknown
3′UTR186TNC Unknown
Mutation nomenclature was numbered based on GenBank cDNA NM_021969.2 and protein
In open reading frame (ORF) of the coding region, nucleotide +1 corresponds to the A of t
In intron region, nucleotide +1 corresponds to the 1st nucleotide of intron.
In 3′UTR region, nucleotide +1 corresponds to the 1st nucleotide downstream of the stop
In 5′UTR and promoter region, nucleotide −1 corresponds to the 1st nucleotide upstream
a) early-onset obesity, b) high birth weight, c) diabetes, d) fatty liver, e) decreased insulinpublished data demonstrate numerous mutations in the human SHP
gene with a variety of physiological consequences (Table 1). Loss of
function mutations in the SHP gene were ﬁrst reported in Japanese
subjects with obesity and diabetes [8]. These mutations included two
frameshiftmutations, H53fsdel10 (deletion of 10bases starting at codon
53 for His) and L98fsdel9insAC (deletion of 9 bases and insertion of a
dinucleotide AC at codon 98 for Leu), one nonsense mutation R34X
(amino acid replacement of Arg codon 34 by terminator), and three
missense mutations, R213C, R216H, and A195S (replacements of Arg
codons 213 and 216 by Cys and His codons, respectively, and Ala codon
195 by Ser). The H53fsdel10, L98fsdel9insAC, and R34X mutations,
found only in subjects with mildly or moderately obesity at onset of
diabetes, were truncations that would completely inactivate the
putative ligand-binding function and also delete C-terminal sequencesity Designation References
Zhou et al., 2010
Cao and Hegele, 2002Hung et al., 2003
Cao and Hegele, 2002 Hung et al., 2003
Echwald et al., 2004
a)b)c)d)e) Nishigori et al., 2001 Enya et al., 2008
Hung et al., 2003 Echwald et al., 2004
Hung et al., 2003
Enya et al., 2008
Zhou et al., 2010
Enya et al., 2008
a)b)c)e) Nishigori et al., 2001Enya et al., 2008
Enya et al.,2008
a) Nishigori et al., 2001Enya et al., 2008
a) Echwald et al., 2004
a)c)e) Nishigori et al., 2001Enya et al., 2008
c) Enya et al.,2008
Echwald et al.,2004
Echwald et al., 2004
Zhou et al., 2010
Cao and Hegele, 2002Hung et al., 2003Mitchell et al.,
2003Echwald et al., 2004Enya et al., 2008Zhou et al., 2010
Enya et al., 2008
Zhou et al., 2010
a) Nishigori et al., 2001Enya et al., 2008
a)c)d)e) Nishigori et al., 2001Enya et al., 2008
Enya et al., 2008
a)b)c)e) Nishigori et al., 2001Enya et al., 2008
Nishigori et al., 2001Enya et al., 2008
Cao and Hegele, 2002
Zhou et al., 2010
Zhou et al., 2010
NM_068804.1 sequences.
he ATG start codon.
codon.
of the start codon.
sensitivity (Nishigori et al., 2001).
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was present in 2 out of 190 control subjects, suggesting that it may be a
polymorphism that is not pathogenic. These ﬁndings suggest that
genetic variations in the SHP gene may contribute to increased body
weight andmutations in the SHP gene are likely associated with insulin
resistance and mild obesity. In addition to playing a possible role in
obesity, SHP may also act as a candidate gene for human lipodystrophy
syndromes. In order to investigate possible disease mutations of SHP in
associationwith human lipodystrophy syndromes, another investigator
sequenced SHP in 15 subjects with lipodystrophy syndromes who had
no mutations in known lipodystrophy genes and 74 clinically normal
Caucasian subjects. This led to the identiﬁcation of four polymorphisms:
SNP [−394]CNT in the promoter, a micro-deletion polymorphism
[−195] delCTGA in the promoter, a missense SNP 541GNC in exon 1
(which changed the amino acid sequence G171A), and SNP 903CNT in
exon 2 [9]. However, no rare SHP coding sequence variants were found
exclusive to patientswith lipodystrophy, suggesting that SHPmutations
are not commonly seen in patients with lipodystrophy who have no
mutations in known disease genes. In 2003, two novel missense
mutations, R34G and R36C, and two common polymorphisms, G171A
and −195CTGAdel, were identiﬁed when the coding regions and 562
bases of the SHP promoter were sequenced in 329 subjects with severe
early-onset obesity in the UK [10]. The 171A allelewas associatedwith a
higher BMI, waist circumference, and children carrying the G171A
variant had higher 30-min insulin responses to a glucose load. The
results suggest that genetic variation in the SHP locus may inﬂuence
birthweight and have effects onBMI, possibly through effects on insulin
secretion. However, another study investigated SHP in 1927 UK
subjects, examining relationships with type 2 diabetes, obesity, and
birth weight, and found that genetic variation in SHPwas unlikely to be
common in the predisposition to diabetes, obesity, or increased birth
weight in UK Caucasians [11]. Moreover, another ﬁve novel SHP
variants, including three missense variants (c.100CNG [p.R34G],
c.278GNA [p.G93D], and c.415CNA [p.P139H]) and two silent variants
(c.65CNT [p.Y22Y] and c.339GNA [p.P113P]) were identiﬁed in 2004
when the entire coding region of SHP was analyzed in a cohort of 750
Danish men with early-onset obesity [12]. The 34G, 93D, and 139H
alleleswere rare variants,whichwere found only amongobese subjects.
Taken together, these results suggest that further large-scale population
studies are necessary to assess the clinical impact of these rare variants
on obesity risk among European subjects. Because mutations in SHP
may be associated with insulin resistance due to both later obesity and
fatty liver in Japanese subjects, the frequencies of SHPmutations in 805
Japanese patients with adult-onset type 2 diabetes (T2DM), 752 non-
diabetic controls, and 93 patients with nonalcoholic steatohepatitis
(NASH) were examined to evaluate the inﬂuence of SHP mutations on
the risk of later development of type 2 diabetes in 2008 [13]. A total of
15 different mutations in 44 subjects, including 6 novel mutations
(c.160CNT [p.Arg54Cys], c.314TNG [p.Val105Gly], c.618GNA [p.Trp206X],Fig. 2. Schematic overview of nuclear receptors (NRs) and transcription receptors (TFs) regu
and the consensus sequences are indicated in the human SHP gene promoter. NRs that targ
(SF-1), liver receptor homolog-1 (LRH-1), farnesoid X receptor (FXR), estrogen receptor
receptor-related receptor γ (ERRγ), and peroxisome proliferator-activated receptor γ (PPAR
protein-1c (SREBP-1c) and circadian locomotor output cycles kaput (CLOCK)/brain and muc.112CNT [p.Arg38Cys], c.134GNC [p.Arg45Pro], c.532GNA [p.
Asp178Asn]) were identiﬁed in this study. Mutations with reduced
activity were found in 2.4% of the diabetic group and in 0.8% of the
control group, suggesting that SHP mutations associated with mild
obesity during childhood increased the susceptibility to type 2 diabetes
later in life for Japanese subjects. Recently, we identiﬁed two novel
missense SHP mutations (p.R38H, p.K170N) in both normal and
CADASIL-like (cerebral autosomal dominant arteriopathy with subcor-
tical infarcts and leukoencephalopathy) patients and found that the
K170 residue played a critical role in controlling SHP ubiquitination and
acetylation which are associated with the protein stability and
repressive function of SHP [14].
3. Inducers of SHP gene expression
Many NRs and TFs have been reported to target the SHP promoter
and regulate SHP gene expression, including steroidogenic factor-1
(SF-1), liver receptor homologue-1 (LRH-1), farsenoid X receptor
(FXR), c-jun, hepatocyte nuclear factor 4α (HNF4α), estrogen
receptor-related receptor γ (ERRγ), E2A gene products (E47, E12
and E2/5), liver X receptor α (LXRα), estrogen receptor α (ERα),
sterol regulatory element-binding protein 1c (SREBP-1c), adaptor
protein (AP1), pregnane X receptor (PXR), the core circadian
component CLOCK-BMAL1, peroxisome proliferator-activated recep-
tor γ (PPARγ), and upstream stimulatory factor-1 (USF-1) (Fig. 2).
One of the earliest studies showed that SF-1 and LRH-1, its close
relative in liver, potently transactivated the SHP promoter. At least
ﬁve SF-1 binding sites were identiﬁed by DNA footprinting studies of
the SHP promoter, and mutagenesis studies demonstrated that each
of the three strongest binding sites was required for SF-1 transactiva-
tion [15]. Since then, many NRs have been identiﬁed to activate the
SHP promoter. Two studies showed that binding of bile acids to FXR
led to the transcriptional activation of SHP. Elevated SHP protein then
inactivated LRH-1 by forming a heterodimeric complex leading to
promoter-speciﬁc repression of SHP, thereby establishing an elabo-
rate autoregulatory negative feedback loop for SHP and a cascade
mediated by nuclear receptors for the maintenance of hepatic
cholesterol catabolism [16,17]. In an attempt to deﬁne the molecular
mechanism underlying the insulin secretion defect in HNF-1α−/−
mice, Shih et al. measured the expression of 50 genes essential for
normal beta-cell functions. They found that both the expression of
SHP and HNF4αwere reduced in adult islets of HNF-1α−/−mice and a
putative HNF4α consensus binding sequence was identiﬁed in the
human and murine SHP promoter [18,19]. Gupta et al. reported that
bile acid-activated JNK pathway played a pivotal role in regulating
CYP7A1 levels in primary rat hepatocytes. Overexpression of the wild-
type c-Jun resulted in increased SHP promoter activity and this effect
was suppressed by mutation of a putative AP-1 (c-Jun) element in the
SHP promoter [20]. Sanyal et al. reported that the SHP promoter waslating the promoter of the human SHP gene. Location of the binding sites of NRs and TFs
et SHP promoter include hepatocyte nuclear factor 4a (HNF4α), steroidogenic factor-1
a (ERα), liver X receptor α (LXRα), upstream stimulatory factor-1 (USF-1), estrogen
γ). TFs that induce SHP expression include E47, c-Jun, sterol regulatory element-binding
scle aryl hydrocarbon receptor nuclear translocator-like 1(Bmal1).
Table 2
Interaction of SHP with other nuclear receptors and transcription factors, or coregulators.
Classiﬁcation Interacting
protein
Methods Target gene References
NR AR Y2H and GST pull down: rSHP/hAR Gobinet et al., 2001
CAR Y2H and GST pull down: mSHP/mCAR Seol et al., 1996
Y2H and GST pull down: mSHP/mCAR,
mSHPΔ128-139/mCAR
Park et al., 2004
GST pull down: mSHP/mCAR ↓CYP2B Bae et al., 2004
DAX-1 Co-IP: hSHP/hDAX-1 Iyer et al., 2006
ERα Y2H and GST pull down: rSHP/hERα Johansson et al., 1999
Y2H, M2H, and GST pull down: SHP/hERα Johansson et al., 2000
Y2H and GST pull down: rSHP/ERα Goodwin et al., 2000
GST pull down: mSHP/hERα Klinge et al., 2002
Co-IP: hSHP/hERα Iyer et al., 2006
ERβ Y2H and GST pull down: rSHP/hERβ Johansson et al., 1999
Y2H, M2H, and GST pull down: SHP/hERβ Johansson et al., 2000
ERRα Y2H and M2H: hSHP/ERRα, mSHP/ERRα Sanyal et al., 2002
ERRβ Y2H and M2H: hSHP/ERRβ, mSHP/ERRβ Sanyal et al., 2002
ERRγ Y2H and M2H: hSHP/ERRγ, mSHP/ERRγ Sanyal et al., 2002
Y2H: rSHP/rERRγ Razzaque et al., 2004
Y2H and GST pull down: mSHP/ERRγ,
mSHPΔ128-139/ERRγ
Park et al., 2004
GST pull down: hSHP/mERRγ ↓YY1 Zhou et al., 2010
FXR M2H and GST pull down: hSHP/mFXR,
mSHP/mFXR
↓PCK1 Lu et al., 2000
GR Co-IP: rSHP/hGR Borgius et al., 2002
HNF4α M2H and GST pull down: mSHP/rHNF4α Lee et al., 2000
M2H and GST pull down: hSHP/rHNF4α,
hSHP/hHNF4α
Boulias et al., 2004
GST pull down: hSHP/hHNF4α ↓AGT↓FBP1 Shimamoto et al., 2004
M2H: SHP/HNF4α ↓MTP Hirokane, et al., 2004
GST pull down: hSHP/hHNF4α ↓ApoCIII↓ApoB Zhou et al., 2010
LRH-1 Y2H: rSHP/mLRH-1 LBD M2H: mSHP/hLRH-1 LBD Lee et al., 2000
M2H and GST pull down: mSHP/m LRH-1 ↓SHP Lu et al., 2000
M2H: SHP/hLRH-1, SHP/mLRH-1 GST pull down:
SHP/hLRH-1
↓CYP7A1 Goodwin et al., 2000
M2H and GST pull down: hSHP/hLRH-1 Lee and Moore, 2002
Y2H: hSHP/hLRH-1 M2H: mSHP/hLRH-1 Brendel et al., 2002
M2H: mSHP/mLRH-1 Boulias et al., 2004
Y2H and GST pull down: mSHP/LRH1,
mSHPΔ128-139/LRH1
Park et al., 2004
SHP/LRH-1 ↓MTP Huang et al., 2007
SHP/LRH-1 ↓cyclinD1 Zhang et al., 2008
GST pull down: hSHP/mLRH-1 ↓SHP Zhou et al., 2010
LXRα GST pull down: mSHP/hLXRα Brendel et al., 2002
LXRβ GST pull down: mSHP/mLXRβ Brendel et al., 2002
Nuf77 M2H and Co-IP: SHP/Nuf77 ↓CYP17 Yeo et al., 2005
PPARα Y2H: rSHP/r PPARα LBD GST pull down:
rSHP/rPPARα
Kassam et al., 2001
PPARγ M2H and GST pull down: hSHP/hPPARα Nishizawa et al., 2002
PXR GST pull down: mSHP/mPXR, mSHP/hPXR ↓CYP3A Ourlin et al., 2003
RARα Y2H: mSHP/RARαLBD M2H: hSHP/hRARαLBD Seol et al., 1996
Y2H: mSHPΔ148/mRARαLBD Seol et al., 1997
RXRα Y2H, M2H, and GST pull down: mSHP/hRXRα Seol et al., 1997
M2H and GST pull down: mSHP/mRXRα Goodwin et al., 2000
SF-1 M2H: hSHP/mSF-1LBD GST pull down: mSHP/mSF-1 Lu et al., 2000
SHP Co-IP: SHP/SHP Iyer et al., 2007
TRβ Y2H: mSHP/TRβ LBD Y2H: hSHP/hTRβ LBD Seol et al., 1996; Seol et al., 1997
TF (Non-NR) ARNT GST pull down: SHP/ARNT ↓CYP1A1↓UGT1A6 Klinge et al., 2001
BETA2/NeuroD Y2H and GST pull down: SHP/BETA2 ↓βGK↓p21 Kim et al., 2004
C-jun Co-IP: rSHP/rC-jun Fiorucci et al., 2004
Jun D Co-IP: rSHP/rJun D Fiorucci et al., 2004
C/EBPα M2H and GST pull down: SHP/N-terminal domain
of C/EBPα Co-IP: SHP/C/EBPα
↓PEPCK Park et al., 2007
Foxo1 GST pull down: SHP N1 or NT/Foxo1 CT Co-IP:
SHP/Foxo1
↓G6Pase Yamagata et al., 2004
HNF3 GST pull down and Co-IP: SHP/HNF3α, SHP/HNF3β,
SHP/HNF3γ
↓G6Pase↓CYP7A1 Kim et al., 2004
NF-κB Y2H, GST pull down and Co-IP: SHP/p65 Kim et al., 2001
Smad3 Y2H, GST pull down and Co-IP: SHP/Smad3 ↓TGFβ↓p21↓smad7↓PAI-1 Suh et al., 2006
Bcl2 Co-IP: mSHP/hBcl2 Zhang et al., 2010
Gli GST pull down and Co-IP: SHP/Gli ↓PTCH1↓Bcl2↓BclxL Kim et al., 2010
P53 GST pull down and Co-IP: SHP/P53 ↓miR34a Lee et al., 2010
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Table 2 (continued)
Classiﬁcation Interacting
protein
Methods Target gene References
Co-regulator
Co-repressor BAF155 GST pull down: mSHP/BAF155 ↓CYP7A1 Kemper et al., 2004
BAF57 GST pull down: mSHP/BAF57 ↓CYP7A1 Kemper et al., 2004
Brm GST pull down and Co-IP: mSHP/Brm ↓CYP7A1 Kemper et al., 2004
Co-IP: mSHP/Brm ↓CYP7A1↓SHP Miao et al., 2009
EID1 Y2H, M2H, GST pull down and Co-IP: rSHP/mEID1 Bavner et al., 2002
Y2H and GST pull down: mSHP/EID1 Park et al., 2004
GST pull down: hSHP/mEID1 Zhou et al., 2010
G9a GST pull down and Co-IP: SHP/G9a Boulias et al., 2004
GST pull down and Co-IP: SHP/G9a ↓CYP7A1↓CYP8B1 Fang et al., 2007
HDAC1 GST pull down: SHP/HDAC1 ↓CYP2B Bae et al., 2004
GST pull down and Co-IP: SHP/HDAC1 Boulias et al., 2004
GST pull down and Co-IP: SHP/HDAC1 Gobinet et al., 2005
HDAC3 GST pull down: SHP/HDAC3 Gobinet et al., 2005
HDAC5 GST pull down: SHP/HDAC5 Gobinet et al., 2005
HDAC6 GST pull down: SHP/HDAC6 Gobinet et al., 2005
mSin3A GST pull down and Co-IP: mSHP/mSin3A ↓CYP7A1 Kemper et al., 2004
GST pull down: SHP/mSin3A ↓CYP2B Bae et al., 2004
SMRT GST pull down: SHP/SMRT Bae et al., 2004
GST pull down: SHP/SMRT ↓CYP2B Bae et al., 2004
SIRT1 M2H, GST pull down and Co-IP: SHP/SIRT1 ↓CYP7A1↓SHP Chanda et al., 2010
Coactivator CBP/p300 Co-IP: SHP/CBP Yeo et al., 2005
M2H and GST pull down: SHP/p300 ↓TGFβ↓p21↓smad7↓PAI-1 Suh et al., 2006
SRC-1 GST pull down: SHP/SRC-D (759–1141), SHP/SRC-E (1101–1441) Kim et al., 2001
Abbreviations: NR, nuclear receptor; TF, transcription factor; Co-IP, coimmunoprecipitation assay; M2H, mammalian two-hybrid system; Y2H, yeast two-hybrid system; h, human;
m, mouse; r, rat.
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et al. found that the basic helix-loop-helix (bHLH) transcription
factors, namely the E2A proteins (E47, E12 and E2/5), differentially
regulated the human and mouse SHP promoters and cooperated with
SF-1 for transcriptional activation of the human SHP promoter [21].
One interesting study revealed a fundamental difference in the
regulation of CYP7A1 in rodent and human hepatocytes and demon-
strated that SHP was regulated directly by LXRα through a DNA
response element that overlapped with the bile acid response element.
This study also provided evidence that different species employed
distinct molecular strategies to regulate cholesterol homeostasis [22].
Lai et al. showed that estrogensdirectly induced theexpressionof SHP in
mouse and rat liver and in human HepG2 cells [23]. SHP promoter
contained one ERα binding site which overlapped with the known FXR
binding site, and the combination of ethynylestradiol plus FXR agonists
did not produce an additive induction of SHP expression in mice. One
study reported differential regulation of the human and mouse SHP
promoters by SREBP-1, which regulates the expression of many genes
involved in cholesterol and fatty acid synthesis [24]. Human SHP
promoter activation by SREBP-1 was mostly mediated by SRE1 (−186
to−195 bp) in the promoter region, whichwas not conserved with the
mouse SHP promoter. In addition, potential PXR response elements
(PXREs) were identiﬁed in the SHP promoter, and PXR formed a
heterodimer with RXR to activate SHP in HepG2 human hepatoma cells
[25]. In 2007, a circadian expression pattern of SHPmRNAwas found in
mouse liver, whichwas coordinately regulated by a core circadian clock
component CLOCK-BMAL1 and LRH-1 [26]. CLOCK-BMAL1 bound to the
E-box (CACGTG)which resulted in stimulationof SHPpromoter activity.
Furthermore, CLOCK-BMAL1 synergistically enhanced LRH-1-mediated
SHP promoter transactivation. The SHP promoter also contains a
functional PPAR response element (PPRE), and the PPARγ ligand
rosiglitazone activated the binding of PPARγ/RXRα heterodimer to the
PPRE and increased SHP expression in primary rat hepatocytes [27].
More recently, HGF and its family member, macrophage-stimulating
factor (MSP),were shown to activate the SHPgenepromoter and induce
SHP mRNA and protein levels. The effect of HGF and MSP on SHP gene
expressionwas demonstrated to bemediated via activation of the AMP-
activatedprotein kinase (AMPK) signalingpathway [28]. Further studiesshowed that USF-1 bound to E-box-1 in the SHP promoter, and HGF
increased USF-1 DNA binding on the SHP promoter via AMPK and DNA-
dependent protein kinase-mediated pathways (Table 2).
To date, many studies have shown that the FXR ligand GW4064
[16,17], androsterone [29], bile acids (BA) and chenodeoxycholic acid
(CDCA) [30,31] were potent inducers of SHP gene expression.
Interestingly, the plant sterol guggulsterone (GS) acted as an antagonist
for the farnesoid X receptor (FXR) and decreased expression of bile acid-
activated genes in HepG2 cells. However, guggulipid treatment in Fisher
rats resulted in signiﬁcant SHP expression activation, which identiﬁed
guggulsteroneas a novel class of FXR ligands characterized by antagonist
activity in coactivator association assays but with the ability to enhance
the action of agonists in vivo [32]. The PPARγ coactivator-1α (PGC-1α)
has been reported to mediate ligand-dependent activation of FXR and
transcription of the SHP gene [33]. In addition, histone methylation,
similar to acetylation,was reported to regulate transcriptional activation
of SHP. The synthetic BA, 6-Ethyl CDCA (6-ECDCA)wasbound to FXRand
activated FXR to interactwithProteinArginineMethyl-Transferase type I
(PRMT1), which induced recruitment of the H4 methylation and up-
regulated SHP mRNA [34]. Whitby et al. demonstrated that the small
molecule GSK8470 acted as a high-afﬁnity ligand for LRH-1 and SF-1 by
using ﬂuorescence resonance energy transfer (FRET) based biochemical
assays, and GSK8470 increased SHP expression in liver cells [35].
SHP plays important roles in negatively regulating the conversion of
cholesterol to bile acids and in regulating the expression of genes with
roles in bile acid transport, lipid metabolism, and gluconeogenesis. In
addition, SHP induces apoptosis in liver and cancer cells. Thus, identifying
SHP ligands may lead to new treatments for cancer, obesity, and
nonalcohol-related fatty liver diseases. In 2007, 6-[3-(1-adamantyl)-4-
hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN) and 4-[3-
(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC)
were identiﬁed as exogenous SHP ligands and their induction of apoptosis
was reported to be mediated by their binding to the SHP protein [36].
Further studies demonstrated that AHPN/3-Cl-AHPC and their analogues
bound speciﬁcally to SHP, and these binding events promoted the
interaction of SHP with a corepressor complex containing the repressor
mSin3A, NCoR, histone deacetylase 4, and heat shock protein 90 [37]. Loss
of SHP or Sin3A expression, while blocking 3-Cl-AHPC-mediated
Table 3
SHP target genes and their function in physiology and disease.
Tissue Target gene Function Reference
Cholesterol and bile acid metabolism
Liver ↓CYP7A1 Bile acid synthesis Goodwin et al., 2000Lu et al., 2000Boulias et al., 2005
↓CYP8B1 Bile acid synthesis Yang et al., 2002Boulias et al., 2005
↓CYP7B1 Bile acid synthesis Boulias et al., 2005
↓BAT Bile acid conjugation Boulias et al., 2005
↓BSEP Bile acid transport Boulias et al., 2005
↓MDR2 Bile acid transport Boulias et al., 2005
↓NTCP Bile acid transport/uptake Denson et al., 2001Boulias et al., 2005
↓SLC10A2 Bile acid transport Neimark et al., 2004
↓ABCB11 Bile acid export Boulias et al., 2005
↓ABCB4 Bile acid export Boulias et al., 2005
↓ABCA1 Cholesterol efﬂux Brendel et al., 2002Boulias et al., 2005
↓APOA1 Reverse cholesterol transport Delerive et al., 2004
↓CETP Cholesteryl easter transfer Luo et al., 2001
↓SCARb1 Cholesterol uptake Boulias et al., 2005
Lipid metabolism and obesity
Liver ↑PPARγ Lipogenesis Nishizawa et al., 2002Boulias et al., 2005Huang et al., 2007
↑SREBP1C Lipogenesis Boulias et al., 2005Huang et al., 2007
↑CD36 Long chain fatty acids uptake Boulias et al., 2005
↑FAS Fatty acid and triglyceride biosynthesis Boulias et al., 2005Huang et al., 2007
↑ACL Fatty acid and triglyceride biosynthesis Boulias et al., 2005
↑ACC-1 Fatty acid and triglyceride biosynthesis Boulias et al., 2005
↑SCD-1 Fatty acid and triglyceride biosynthesis Boulias et al., 2005
↓MTP Plasma lipoprotein secretion Hirokane et al.,2004Huang et al., 2007Pan et al., 2010
Brown adipose tissue ↓UCP1 Mitochondrial thermogenesis and biogenesis Wang et al., 2005
↓PGC1α Thermogenesis Wang et al., 2005
↓Dio2 Thermogenesis Wang et al., 2005Tabbi-Anneni, 2010
↑HSL Lipolysis Tabbi-Anneni, 2010
↑LPL Thermogenesis Tabbi-Anneni, 2010
↑β1AR Mitochondrial thermogenesis and biogenesis Tabbi-Anneni, 2010
White adipose tissue ↓SREBP1 ↓LPL Lipid accumulation Tabbi-Anneni, 2010
Liver ﬁbrosis
Liver ↓alpha1 (I) collagen ↓Α-SMA Fibrogenesis Fiorucci et al., 2004
↓TIMP-1 Regulation of metalloproteinase activity Fiorucci et al., 2005
↓PAI-1 Fibrogenesis Chanda et al., 2009
Glucose metabolism
Liver ↓PEPCK Rate limiting gluconeogenic enzyme Borgius et al., 2002Park et al., 2007Chanda et al., 2009
↓G6Pase Regulate blood glucose levels Kim et al., 2004Lee et al., 2008Chanda et al., 2009
↓FBP1 Gluconeogenesis Yamagata et al., 2004
↓LGK Hepatic glucokinase Kim et al., 2009
Drug metabolism
Liver ↓CYP2B Drug and hormone metabolism Bae et al., 2004
↓CYB3A Drug and hormone metabolism Ourlin et al., 2003
Cancer
Liver ↓CyclinD1 Cell cycle Zhang et al., 2008
↓Bcl2 Apoptosis Zhang et al., 2010
Breast ↓CYP19 Estrogen production Kovacic et al., 2004
Other ↓Gli Hedgehog signaling pathway Kim et al., 2010
↓: inhibition; ↑: induction.
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Furthermore, 3-Cl-AHPC inductionof c-Fos andc-Junexpressionaswell as
NF-kappaB activation were dependent on SHP protein levels [38].
Induction of apoptosis by SHP required the presence of the terminal
CO2H group on the AHPNor AHPC scaffold, and optimal apoptotic activity
also required both the 3′-(1-Ad) and 4′-OH groups [39]. Recent studies
have also shown that AHPN and 3-Cl-AHPC induced SHP mRNA
expression in Huh7 human liver cancer cells via increasing LRH-1 protein
stability and enhancing the recruitment of LRH-1 to the SHP promoter
[40].We also found that in vivo administration of AHPN and 3-Cl-AHPC to
the mice increased SHP expression in liver (Table 3).
4. SHP in transcriptional regulation
SHP predominantly functions as a transcriptional repressor of gene
expression bydirectly binding to a variety of NRs, including LRH-1, HNF4,ERRs, LXRs, PPARs, GR, ERs, TRβ, RARα, FXR, PXR, CAR, AR, NGFI-B
(Nur77) andRXRswhichare the commonheterodimerizationpartner for
many NRs (Fig. 3). To date, at least three distinct repressionmechanisms
appear likely to explain the inhibitory function of SHP on the
transcription of NR target genes. The NR-binding mode of SHP implies
that interfering with the AF-2 domain of NRs through two functional
LXXLL-related motifs, resulting in direct competition with coactivator
binding, is associated with the inhibitory mechanism of SHP. This mode
of inhibition appears pronounced in the case of SHP inhibition on ERs,
RXR, LRH-1, HNF4, AR, LXRs, ERRs, GRs and Nur77 induced transcription
[4,6,17,41–53]. Two possibilities have been considered in this respect: 1)
SHP and AF-1/2 coactivators may compete for a common site; or 2)
binding of SHP to the receptor may induce conformational changes
leading to the dissociation of AF-1/2 coactivators from the receptors.
Interestingly, the competition with coactivator by SHP is not limited to
NR targets. A few other TFs have been reported to interact with SHP. One
Fig. 3. Model of three distinct transcriptional repression mechanisms for SHP. SHP represses nuclear receptor (NR) or transcription factor (TF) mediated transactivation by
competition for coactivator binding to NR (I), recruitment of SHP-associated corepressors (II), and inhibition of DNA binding (III). SHP can utilize these three inhibitory steps
alternatively or sequentially in a cell type and target gene speciﬁc manner.
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transcription factor BETA2/NeuroD by competing with coactivator p300
for binding to BETA2/NeuroD [54]. Another example is that SHP
interacted with Foxo1 and led to the repression of Foxo1-mediated
G6Pase transcription by competing with a coactivator cAMP response
element-binding protein [55]. In addition, SHP mediates inhibition of
transforming growth factor-beta (TGF-β)-induced gene expression via a
direct repression of Smad3 transactivation by competing with its
coactivator p300 [56].
Although coactivator competitionon theAF-2domainmight appear to
be important for inhibition, SHP has been suspected to act as a direct
transcriptional repressor by recruiting conventional corepressors as SHP
contains a strong transcriptional repression domain at its C terminus. The
requirement of both these twomodeshas been found in SHP inhibitionon
manyNRs such as HNF4, ERs and LRH-1 [4,44,57]. SHPmight utilize these
two distinct inhibitory steps in a cell type and target gene dependent
manner. Themouse E1A-like inhibitor of differentiation 1 (EID1) acting as
a candidate coinhibitor for SHP has been isolated in screens for SHP
corepressors [58]. Histone acetyltransferases and histones might act as
targets for EID1 action and SHP inhibition of transcription might involve
EID1 antagonism of CBP/p300-dependent coactivator functions. Site-
speciﬁc modiﬁcation of nucleosomal histones plays a central role in the
formation of transcriptionally active and inactive chromatin structures.
Components of histone deacetylases (HDACs)/corepressor complexes are
other important coinhibitors for SHP. For example, one study showed that
mSin3A and a Swi/Snf complex containing Brm as a central ATPase were
recruited to the CYP7A1 promoter and SHP was associated with the
mSin3A-Swi/Snf complex by direct interaction with Brm and mSin3A
through its repression domain to inhibit CYP7A1 gene expression [59].
SHP has also been shown to be associated with unmodiﬁed and lysine
9-methylated histone-3 and to functionally interact with HDAC1 and the
G9a methyltransferase, which led to histone deacetylation, followed by
H3-K9 methylation and stable association of SHP itself with chromatin
[60]. Another study showed G9a was recruited to and H3K9 was
methylated at the CYP7A1 promoter in a SHP-dependent manner. This
study established a critical role for G9a methyltransferase, histone
deacetylases, and the Swi/Snf-Brm complex in the SHP-mediated inhibi-
tion of hepatic bile acid synthesis via coordinated chromatinmodiﬁcation
at target genes [61]. A recent interesting study showed SHP recruited
SIRT1, a class III histone deacetylase on LRH1 target gene promoters and
SIRT1 deacetylated template-dependent histone H3 and H4 to inhibit
transcriptionof LRH1 target genes [62]. Theﬁnding that anHDAC inhibitor
affected intrinsic SHP repressive activity provided further evidence for the
involvement of HDACs in SHP-mediated repression of transcription [63].
Moreover, SHP binding to some NRs resulting in the dissociation of
the SHP-NRs complex from certain promoters is the third possiblemode
of repression by SHP. For example, SHP has been shown to inhibit DNA
binding and transcriptional activation by repressing RAR-RXR hetero-
dimers, RAR-PXR heterodimers, agonist dependent ERα dimerization
and HNF4α homodimerization [2,64–66]. Interestingly, SHP also
interacts with some TFs and inhibits DNA binding and transactivation.One example is the SHP-mediated suppression of agonist-activated
arylhydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT)
activity by inhibiting AHR/ARNT-DNA binding [67]. HNF-3, JunD and
C/EBPαwere also reported to be repressed by SHP via inhibition of DNA
binding [68–70].
Most studies report that SHPacts as a repressor of gene transcription.
In contrast, SHP has been found to activate the nuclear factor-kappa B
(NF-κB) in resting macrophage cells treated with oxidized low density
lipoprotein (oxLDL) [71]. Moreover, SHP was also reported to up-
regulate the transcriptional activityof PPARbydirectly binding theDBD/
hinge region of PPAR [7]. The authors suggested that the following
mechanisms might be involved: 1) SHP might directly inhibit the
binding of the PPARγ–RXRα complex to PPRE; 2) SHP might compete
with the corepressors for binding to PPARγ; or 3) SHP may possess its
own activating function at its C terminus.
5. SHP in microRNA regulation
MicroRNAs (miRNAs, miRs) are recently discovered small 21–
23 nts noncoding RNAs that regulate gene expression primarily by
translational repression of target mRNAs after binding their 3′-
untranslated regions (3′-UTRs) by partial base pairing [72]. They are
generally produced from much larger Pol II RNA transcripts [73–76].
MiRNAs participate in the regulation of many cellular processes and
changes of their expression are frequently observed in human
diseases including cancers [77–79]. Despite intensive studies on
their physiological and pathological functions [80], the molecular
mechanisms of howmiRNA gene transcription is regulated by TFs and
NRs remain largely unknown. Recent studies demonstrate that SHP
plays an important role in regulating the transcription of several
miRNAs. We ﬁrst showed that the 3′-coding region of pri-miR-433
served as the promoter region of pri-miR-127 [73,81], and SHP
inhibited ERRγ transactivation on the miR-433 and miR-127 promo-
ters, resulted in repression of these two miRNAs [81]. This study
revealed a novel mechanism by which the coupled miR-433 and miR-
127 genes were regulated by nuclear receptors in a compact genomic
space. Further multiple sequence alignments showed that the
precursors of miR-433 and of miR-127 exhibited 95% and 100%
similarity, respectively, in human, chimpanzee, horse, dog, monkey,
rat, cow, and mouse, indicating that the miR-433/127 loci might have
evolved from a common gene of origin [82]. Another study from our
lab revealed a novel cascade “dual inhibitory” mechanism governing
miR-206 gene transcription by SHP: SHP inhibition of ERRγ led to
decreased YY1 expression and the de-repression of YY1 on AP (c-Jun
and c-Fos) activity, ultimately leading to the activation of miR-206,
which elucidates a cascade regulatory mechanism governing miRNA
gene transcription by NRs [74]. A more recent study showed that FXR
induced expression of SHP, which in turn resulted in repression of p53
occupancy at the miR-34a gene promoter, leading to the positive
regulation of the NAD-dependent deacetylase Sirtuin 1 (SIRT1) in the
liver [83]. This study demonstrated a role of the FXR/SHP pathway in
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34a levels in obese mice contribute to decreased SIRT1 levels. The
authors proposed that manipulation of this regulatory network might
be useful for treating metabolic disease and cancer.
6. SHP in metabolism
Numerous independent in vitro studies have identiﬁed a number
of interaction partners for SHP, indicating the potential for SHP to
regulate a wide array of genes in various biological pathways (Fig. 4).
In line with this, an in vivo study performing global gene expression
proﬁling combined with chromatin immunoprecipitation assays in
transgenic mice constitutively expressing SHP in the liver demon-
strates that SHP is a pleiotropic regulator, inﬂuencing multiple target
genes involved in diverse biological processes in a direct or indirect
manner, including regulation of metabolic pathways, stress and
inﬂammatory response, detoxiﬁcation and cell cycle control [84].
6.1. SHP in feedback regulation of bile acid synthesis
Bile acids are the end products of the cholesterol catabolic pathway
and their synthesis in the liver requires the coordinated actions ofmany
enzymes. SHP was shown to regulate genes involved in bile acid
synthesis (CYP7A1, CYP8B1, and CYP7B1), conjugation (BAT), and
transport (BSEP, MDR2, NTCP, SLC10A2, ABCB11, ABCB4, ABCA1, CETP,
and SCARB1) [16,17,47,84–89]. At least two pathways of bile acid
biosynthesis have been described. The ﬁrst and rate-limiting enzyme is
cytochrome P450 enzyme cholesterol 7α-hydroxylase (CYP7A1) in the
endoplasmic reticulum initiated neutral pathwaywhich is regulated by
FXR and LXR [16,90,91]. The alternative acidic pathway is initiated in the
mitochondria by the enzyme sterol 27-hydroxylase (CYP27A1),
followed by distinct oxysterol 7α-hydroxylase (CYP7B) [92,93]. TheFig. 4. Integrated view of SHP as a central transcriptional coregulator in diverse physiolog
inhibitory pathways are shown as broken red lines. FA, fatty acid; TG, triglyceride; VLD
hydroxylase; G6P, glucose-6-phosphatase; HNF-4α, hepatocyte nuclear factor 4 α; JNK, c
microsomal triglyceride transfer protein; PEPCK, phosphoenolpyruvate carboxykinase; PP
SREBP-1c, sterol regulatory element-binding protein-1c; WAT, white adipose tissue; and BAfeedback inhibition of CYP7A1 expression is regulated by multiple bile
acid-activated signaling pathways, including the FXR/SHP nuclear
receptor cascade [16,17], cellular kinases [20,94–96], and the ﬁbroblast
growth factor 15/19 (FGF15/19) [97,98]. SHP has been implicated as a
key downstream regulator in all of these inhibitory pathways.
The function of CYP7A1 in bile acid biosynthesis has been studied
extensively. Bile acids, steroid hormones, inﬂammatory cytokines,
insulin, and growth factors have been found to inhibit CYP7A1
transcription through the promoter region. Two bile acid response
elements (BARE) that are putative nuclear receptor binding sites were
identiﬁed in theproximal promoter of rat CYP7A1 [99]. BARE-I is located
at−73 to−55 of the rat CYP7A1 promoter containing LXR binding site
in all species except humans. This has been conﬁrmedby theﬁnding that
bile acid synthesis was increased inwild-typemice but not in LXRα null
mice fed a high cholesterol diet [90]. In contrast, LXRα did not bind the
human CYP7A1 promoter and the hCYP7A1 promoter was not induced
by feeding cholesterol to transgenicmice harboring the gene [100–102].
A subsequent study has shown that activation of LXRα repressed
CYP7A1 expression through induction of SHP in primary cultures of
human hepatocytes [22]. These ﬁndings indicate that there are
fundamental differences in the regulation of CYP7A1 and cholesterol
homeostasis in rodents and humans. While rodents appear to deal with
excess cholesterol by stimulating its conversion to bile acids for
excretion from the body via stimulating CYP7A1 expression, humans
may have evolved an alternate strategy against excessive cholesterol, in
which the absorption of cholesterol in the intestine is reduced through
decreased bile acid production via repression of CYP7A1 expression.
BARE-II contains a HNF4α binding site located in a region from−149 to
−118 of the rat CYP7A1promoter,whichhas an18nucleotide sequence
that is completely conserved in humans [103]. In the CYP7A1 and
CYP8B1 promoters, the HNF4α binding site overlaps with a binding site
for LRH-1. In the FXR/SHP pathway, bile acids bind to the bile acidical pathways in the liver. Activation pathways are shown as broken blue arrows and
L, very low density lipoprotein; CYP7A1, cytochrome P450 enzyme cholesterol 7α-
-jun N-terminal kinase; LRH-1, liver receptor homolog-1; LXR, liver X receptor; MTP,
ARγ, peroxisome proliferator-activated receptor γ; SHP, small heterodimer partner;
T, brown adipose tissue.
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LRH-1 and HNF4α, results in repression of CYP7A1 and SHP [16,17]. In
this process, induced SHP inhibits transcription of CYP7A1 by coordi-
nately recruiting the chromatin modifying cofactors, mSin3A/HDAC
corepressors, a class III histone deacetylase SIRT1, G9a methyltransfer-
ase, and Swi/Snf-Brm chromatin remodeling complex to the CYP7A1
promoter [59,61,62,104]. However, two recent studies using liver-
speciﬁc conditional knockouts of LRH-1 inmice suggest that LRH-1may
not be essential for bile acid inhibition of CYP7A1. Mataki et al. reported
that while the expression of CYP8B1 was almost abolished in mouse
liver lacking LRH-1, the expression of CYP7A1 remained unchanged
[105]. Lee et al. generated conditional knockouts of LRH-1 in either
hepatocytes or intestinal epithelium and demonstrated that LRH-1
deﬁciency in hepatocytes had no signiﬁcant effect on either basal
CYP7A1 expression or its repression by FXR [106]. However, basal
CYP8B1mRNA levelswere signiﬁcantly decreased and this decreasewas
accompanied by a decreased concentration of taurocholic acid and
increased levels of tauromuricholic acids in the bile acid pool. These
results indicate that LRH-1 is required for FXR inhibition of CYP8B1 gene
transcription, but may not be involved in FXR inhibition of CYP7A1,
which also suggests different roles for CYP7A1 andCYP8B1 in regulating
the bile acid pool size and composition.
While this SHP-dependent regulatory cascade accounts for the
inhibitory effects of bile acid synthesis, studies from two different
groups suggest that other pathways are also involved. One study
reported that SHP-deﬁcient mice showed abnormal accumulation and
increased synthesis of bile acids due to de-repression of the rate-
limiting CYP7A1 and CYP8B1 hydroxylase enzymes in the biosyn-
thetic pathway. Dietary bile acids induced liver damage and restored
feedback regulation. Reduction of the bile acid pool with cholestyr-
amine enhanced CYP7A1 and CYP8B1 expression. The authors
proposed that three negative regulatory pathways controlled bile
acid synthesis, one was mediated by SHP, and two were SHP
independent and invoked by liver damage and changes in bile acid
pool size [94]. Another study of mice lacking the SHP gene showed
that they exhibited mild defects in bile acid homeostasis and failed to
repress CYP7A1 expression in response to a speciﬁc agonist for the
bile acid receptor FXR. However, this repression was retained in the
SHP−/− mice fed bile acids, demonstrating the existence of compen-
satory repression pathways for bile acid signaling. Further studies
suggested that both the c-Jun N-terminal kinase JNK and PXR
pathways might be involved in CYP repression by bile acids in SHP
null animals [95]. In addition, bile acids have been shown to inhibit
CYP7A1 by activating PKB (AKT) kinases [96]. It should be noticed that
bile acids also activate the steroid and xenobiotic receptor PXR, which
induces human cytochrome P4503A4 (CYP3A4) in drug metabolism
and CYP7A1 in bile acid synthesis in the liver. Rifampicin, a human
PXR agonist, inhibits bile acid synthesis and has been used to treat
cholestatic diseases. However, rifampicin reduced CYP7A1 and SHP
mRNA expression suggesting that SHP was not involved in the PXR
inhibition of CYP7A1. Further investigation showed that activation of
PXR by rifampicin promoted the interaction of PXR with HNF4α and
blocked PGC-1α activation by HNF4α, resulting in inhibition of
CYP7A1 gene transcription [107].
Bile acids repressed CYP8B1 transcription by reducing the transacti-
vation of HNF4α by SHP contributes to the repression of bile acid
production [108]. In contrast to the increased sensitivity predicted from
the loss of negative feedback regulation, the SHP−/− mice were
relatively resistant to the hepatotoxicity of a diet containing 0.5% cholic
acid and themore severe effects of a diet containingboth0.5% cholic acid
and2%cholesterol in long term treatments. Thiswas associatedwith the
decreased hepatic accumulation of cholesterol and triglycerides in
SHP−/− mice. CYP8B1 was strongly re-expressed in the SHP−/− mice,
but not in wild-type mice, fed either diet containing bile acid. This
contrasts to the strong repression of CYP8B1 observed with short term
bile acid feeding, aswell as the effects of long term feeding on other bileacid biosynthetic enzymes such as CYP7A1. The induction of CYP8B1
could contribute to the decreased toxicity of chronic bile acid treatment
by increasing the hydrophilicity of the bile acid pool. These results
identiﬁed an unexpected role for SHP in hepatotoxicity and suggested
new approaches to modulating effects of chronically elevated bile acids
in cholestasis [109].
Bile acid-activated FXR was demonstrated recently to induce
expression of FGF15/19 (FGF15 is the mouse homolog of human
FGF19) in the small intestine and secreted FGF15 repressed CYP7A1
transcription in liver through a mechanism involving the membrane
FGF receptor 4 (FGFR4) and SHP [98]. The role of this intestinal FXR/
FGF15 pathway has been further conﬁrmed in intestine-speciﬁc FXR
knockoutmice [110]. In this study, the FXR agonist GW4064 repressed
CYP7A1 in liver-speciﬁc FXR knockout mice but not in intestine-
speciﬁc FXR knockout mice, indicating that the activation of intestinal
FXR but not liver FXR is required for bile acid inhibition of CYP7A1
gene expression. In contrast, FXR-mediated repression of CYP8B1 was
more preferentially dependent on the liver FXR/SHP pathway and less
dependent on the intestine FXR/FGF19/FGFR4 pathway indicating
differences in bile acid feedback repression of CYP7A1 and CYP8B1.
While the induction of SHP gene expression by increased bile acids is
well established, whether SHP protein activity is also modulated
remains largely unknown. A recent study showed that SHP was a
rapidly degraded protein via the ubiquitin-proteasomal pathway and
that bile acids or bile acid-induced FGF19 increased stability of hepatic
SHP by inhibiting proteasomal degradation in an extracellular signal-
regulated kinase (ERK)-dependent manner. SHP was ubiquitinated at
Lys122 and Lys123, and mutation of these sites altered its stability and
gene repression activity. Furthermore, SHPwasphosphorylatedat Ser26
by ERK during bile acid treatment, andmutation of this site dramatically
decreased the stability of SHP. Moreover, the stability of SHP was
abnormally elevated in ob/ob mice and diet-induced obese mice. The
authors proposed the important role for regulation of SHP stability in
bile acid signaling under normal conditions, and that abnormal
stabilization of SHPmight be associatedwith obesity and diabetes [111].
6.2. SHP in lipid metabolism and obesity
Cellular cholesterol and lipid homeostasis is tightly controlled by a
complex network of transcriptional programs regulating their pro-
duction and clearance, which depends on a large number of nuclear
receptor familymembers. For instance, increased activity of PPARγhas
been directly associated with steatosis [112]. To date, multiple lines of
evidence demonstrate that SHP regulates several metabolic pathways
involved in fatty liver and obesity by acting as a transcriptional
repressor of other nuclear receptors [113,114]. One untypical example
is that SHP gene augmented PPARγ transactivation [7] and the acute
PPARγ overexpression resulted in marked hepatic lipid accumulation
[112]. SREBP-1c is another important factor in regulating the lipogenic
program in liver and is also a target of SHP. It has been shown that
down-regulation of SREBP-1c expression by SHP was mediated via
FXR activation by either natural or synthetic FXR agonists, followed by
the down-regulation of LXRα and LXRβ, and consequently repressing
other transcriptional factors to stimulate SREBP-1c transcription [113].
In agreement with these observations, in transgenic mice constitu-
tively expressing SHP in the liver, SHP was shown to affect genes
involved in bile acid conjugation, transport and lipogenic pathways.
Constitutive SHP expression led to the depletion of hepatic bile acid
pool and accumulation of triglycerides in the liver, whichmay account
for the direct repression of downstream target genes and the bile acid
sensor FXR, and an indirect activation of the major regulators of
lipogenic genes such as PPARγ and SREBP-1c via SHP [84]. Further-
more, the mRNA levels of other genes involved in fatty acid and
triglyceride biosynthesis, such as the fatty acid synthase (FAS), ATP
citrate lyase (ACL), acetyl-CoA carboxy-lase (ACC-1) and stearoyl-CoA
reductase (SCD1), were also increased signiﬁcantly in SHP-transgenic
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transcription via LXR, and this response was blocked by increased SHP
and that FAS mRNA was overexpressed in SHP−/− mice [114].
Microsomal triglyceride transfer protein (MTP) is a dedicated
chaperone required for biosynthesis of apolipoprotein B (apoB), and is
transcriptional repressed by SHP via interactions with HNF4α and
LRH-1 [52,115]. Our previous study showed that the deletion of SHP in
obese leptin-deﬁcient mice (ob/ob), an animal model of severe
obesity and insulin resistance, prevented the development of
nonalcoholic fatty liver by enhancing lipid secretion (MTP) as well
as decreasing de novo hepatic fatty acid synthesis (SREBP-1c and FAS)
and uptake (PPARγ). These ﬁndings established a major function of
SHP in modulating hepatic lipid synthesis and transport [115].
Several studies demonstrated that plasma triglycerides show diurnal
variations [116–118]. MTP expression and plasma lipids underwent
diurnal regulation and exhibited peaks and nadirs at similar times,
indicating that circadian changes inMTP could contribute to plasma lipids
circadian rhythmicity [118]. Oiwa and associates reported rhythmic
expressionof SHP in themouse liver. Theydemonstrated that clock genes,
namely, circadian locomotor output cycles kaput (CLOCK) and brain and
muscle aryl hydrocarbon receptor nuclear translocator-like 1 (Bmal1),
bound to the E-box elements present in the SHP promoter and
synergistically activated SHP transcription with LRH-1, which was in
turn suppressed by SHP itself [26]. However, little was known about the
mechanisms controlling diurnal changes in plasma lipids and MTP. To
address this issue, Pan et al. examined the role of the CLOCK gene in the
diurnal regulation ofMTP, and found that CLOCKup-regulation of SHP led
to a consequent suppression of MTP expression resulting in MTP diurnal
changes [119]. This studypoints to the importanceof bothCLOCKandSHP
in the circadian regulation of MTP and plasma triglycerides, and further
indicates that disruptions in circadian rhythms might induce hyperlip-
idemia. Mice with the clock gene knocked out are prone to developing
metabolic syndrome. These ﬁndings have important applications in
understanding why some night shift workers are at increased risk for
developing the metabolic syndrome [120–122].
To further characterize the effect of loss of SHP in protecting
against dyslipidemia, Hartman et al. crossed the SHP−/− mice with
the LDLR−/−mice and found that the elevated levels of VLDL and LDL
cholesterol induced by a lipid rich western diet in LDLR−/−mice were
greatly reduced by SHP deﬁciency in LDLR−/−SHP−/− mice [123]. In
addition, hepatic inﬂammatory marker genes including TNFα, VCAM
and ICAM-1 were induced by the same diet in LDLR−/−mice but their
induction was completely blocked in LDLR−/−SHP−/− mice. The
authors conﬁrmed that the loss of SHP expression speciﬁcally in
hepatocytes was responsible for protecting against dyslipidemia by
using liver-speciﬁc SHP-deleted mice.
Obesity is the result of an imbalance between energy intake and
expenditure. Energy intake is mainly dependent on food ingestion and
energy expenditure depends on several factors, including exercise and
heat production, or so-called adaptive thermogenesis. Brown adipose
tissue (BAT) is the major site for adrenergic mediated adaptive
thermogenesis involving the uncoupling protein-1 (UCP1), whereas
white adipose tissue (WAT) is mostly implicated in the regulation of
lipid storage and catabolism [124,125]. Previous study showed that
basal gene expression of UCP1 and PGC-1α was increased in BAT of
SHP−/−mice and this was associated with increased oxygen consump-
tion, heat production and decreased obesity, indicating that SHPmay be
a negative regulator of energy utilization [126]. To further investigate
the effects of SHP activation in adipose tissues, we generated transgenic
mice overexpressing SHP inWAT and BAT, and unexpectedly found the
enhanced whole body energy metabolism and up-regulation of β1AR
and PGC-1α in BAT of the young mice [127]. On the other hand, SHP
activation inWAThad a dominant role in obesitywhich exacerbated the
obese phenotype associated with the high-fat diet. Developing small
molecule therapeutics that antagonize the effect of SHP may provide a
new approach for treating obesity.6.3. SHP in liver ﬁbrosis
Hepatic ﬁbrosis, the precursor to cirrhosis, represents the wound
healing response to liver injury from a wide variety of etiologies, and
includes components of both increased and altered deposition of
extracellular matrix (ECM) and wound contraction. Remarkable prog-
ress has been made in identifying the cellular sources of ECM and the
pathways regulating the regression of ﬁbrosis [128]. Following hepatic
injury, hepatic stellate cells (HSCs), the major source of ECM in the liver,
become activated and undergo a progressive process of trans-differen-
tiation froma resting, fat-storingphenotype toward amyoﬁbroblast-like
phenotype, characterized by increased expression of ﬁbroblastic cell
markers such as α-smooth muscle actin (α-SMA) [129,130].
Several studies demonstrated that SHP has a preventative role in
liver ﬁbrosis. One early study showed that exposure of HSCs to FXR
ligands caused a 3-fold increase of SHP, reduced alpha1 (I) collagen
and TGF-β1 by approximately 60–70% and abrogated alpha1(I)
collagen mRNA up-regulation induced by thrombin and TGF-β1.
SHP bound JunD and inhibited DNA binding of adaptor protein (AP)-1
induced by thrombin. Based on these ﬁndings, the authors proposed
that FXR ligands might represent a novel therapeutic option to
treat liver ﬁbrosis [69]. In addition, 6-ethyl chenodeoxycholic acid
(6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxy-
cholic acid (CDCA), modulated tissue metalloproteinase inhibitor
(TIMP)-1 and matrix metalloprotease (MMP)-2 expression and
activity in HSCs and in the liver of rats rendered cirrhotic by a 4-
week treatment with CCl(4). Further studies showed that activation/
overexpression of FXR caused a SHP-dependent inhibition of JunD
binding to its consensus element in the TIMP-1 promoter. Conse-
quently, inhibition of TIMP-1 expression by SHP enhanced the
sensitivity of HSCs to proapoptogenic stimuli, demonstrating that a
FXR-SHP regulatory cascade promoted the development of a
quiescent phenotype and increased apoptosis of HSCs [131].
However, one study investigated the impact of genetic FXR
ablation in four different mouse models of hepatic ﬁbrosis, including
CCl(4), 3,5-diethoxycarbonyl-1,4-dihydrocollidine feeding, common
bile duct ligation (BDL), or Schistosoma mansoni-infection. The
authors found that FXR deﬁciency had no effect in CCl(4) treated
and Schistosoma infected mice, but signiﬁcantly decreased liver
ﬁbrosis of the biliary type (common bile duct ligation, 3,5-diethox-
ycarbonyl-1,4-dihydrocollidine feeding). Moreover, FXR protein was
undetectable in mouse and human HSCs and portal myoﬁbroblasts
(MFBs). This study suggested that the loss of FXR signiﬁcantly reduced
ﬁbrosis of the biliary type, but had no impact on non-cholestatic liver
ﬁbrosis. Since there is no FXR expression in HSCs and MFBs during
liver ﬁbrosis, the authors questioned the justiﬁcation of using FXR
ligands as therapeutics for hepatic ﬁbrosis [132].
Loss of SHP resulted in increased sensitivity to liver damage
induced by bile duct ligation (BDL) further conﬁrmed the protective
effect of SHP in ﬁbrosis. SHP−/−mice showed increased sensitivity in
this model of acute obstructive cholestasis, with greater numbers of
bile infarcts and higher mortality than wild-type C57BL/6mice. At 3 h,
CYP7A1 expression still remained elevated in SHP−/− with respect to
wild-type mice, and the hepatic and serum bile acid levels and total
hepatobiliary bile acid pool were signiﬁcantly increased. The
increased sensitivity of mice lacking SHP contrasts with the decreased
sensitivity of mice lacking FXR to BDL, which has been associated with
decreased intraductal pressure and fewer bile infarcts [133].
Plasminogen activator inhibitor type I (PAI-1) is a marker of the
ﬁbrinolytic systemand serves as apossiblepredictor for hepaticmetabolic
syndromes. Recently, Fenoﬁbrate, a peroxisome proliferator-activated
receptor alpha (PPARα) agonist, has been shown to increase SHP gene
expression in cultured liver cells and in normal and diabetic mouse liver
by activating the adenosine monophosphate-activated protein kinase
(AMPK) signaling pathway in a PPARα-independent manner. Further-
more, administration of TGF-β or a methionine-deﬁcient and choline-
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C57BL/6 mice was reversed by fenoﬁbrate via AMPK-mediated induction
of SHP. This was accompanied by a dramatic decrease in PAI-1messenger
RNA (mRNA) and protein expression along with other ﬁbrotic marker
genes, which was not observed in SHP−/− treated with fenoﬁbrate [134].
Theseﬁndings raise the possibility that synthetic ligands that activate SHP
might have antiﬁbrotic effect in some types of liver diseases.
6.4. SHP in glucose metabolism
The maintenance of glucose homeostasis depends on the coordi-
nation and integration of several physiological systems to balance
glucose production in the liver and glucose use in peripheral tissues.
This process is normally controlled by the balanced secretion and
action of insulin on one side and glucagon, epinephrine, cortisol, and
growth hormone on the other [135]. A variety of transcription factors
and cofactors such as PGC-1α [136] are known to regulate transcrip-
tion of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate
carboxykinase (PEPCK), which encodes a rate-determining enzyme in
hepatic gluconeogenesis. Speciﬁc functions of SHP in gluconeogenesis,
particularly in the liver, were suspected based on the abundance of
mRNA in this tissue and its interaction with NRs implicated in liver
gluconeogenesis. The glucocorticoid receptor (GR) plays an important
role in regulating blood glucose levels in mammals, and has been
identiﬁed as a downstream target for SHP inhibition. The fact that SHP
antagonizes the GR coactivator PGC-1α coactivation leading to
inhibition of PEPCK expression implies a physiologically relevant
role for SHP in modulating hepatic glucocorticoid action [46]. In
addition, it has been shown that SHP is involved in the repression of
G6Pase and PEPCK gene expression via inhibition of the forkhead
transcription factors hepatocyte nuclear factor-3 (HNF3) [68] and
HNF6 [137]. Another study showed that SHP repressed C/EBPalpha
(CCAAT/enhancer-binding protein alpha) driven transcription of
PEPCK through a direct interaction with the C/EBPalpha protein,
resulting in the inhibition of PEPCK gene transcription [70]. This
observation provides further evidence that SHPhas amajor function in
regulating hepatic gluconeogenesis. Other important targets of SHP in
glucose metabolism are the forkhead transcription factor FOXO1, the
basic helix-loop-helix transcriptional factor BETA2/NeuroD, and the
aryl hydrocarbon receptor (AHR)/nuclear translocator (ARNT)
[54,55,67].
The observation that bile acids inhibit the expression of gluconeo-
genic genes, including G6Pase, PEPCK, and fructose 1, 6-bis phospha-
tase (FBP1), in a SHP-dependent manner and the absence of this
repression in both FXR−/− and SHP−/− mice indicate that FXR-SHP
nuclear receptor cascade also regulates glucose metabolism [55,138].
Reporter assays demonstrated that overexpression of SHP and
chenodeoxicholic acid treatment down-regulated PGC-1 promoter
activity via a member of the forkhead transcription factors, Foxo1,
Foxo3a, and Foxo4 [139]. The above ﬁndings reveal that bile acids
inhibit hepatic gluconeogenesis in a SHP-dependent manner. In
addition, hyperglycemia, insulin resistance, and insulin response to
glucose, as well as dyslipidemia, were signiﬁcantly ameliorated in a
type 2 diabetes animal model by treatment with the bile acid binding
resin colestimide provides further evidence for a link between bile
acids and glucose metabolism [140]. These observations suggest that
the bile acid metabolism pathway could be a novel target in treating
obesity, insulin resistance, and type 2 diabetes.
AMP-activated protein kinase (AMPK) is a serine/threonine kinase
that regulates hepatic glucose and lipid homeostasis by affecting a
diverse set of target genes associated with these metabolic pathways.
Metformin, an antidiabetic drug widely used for the treatment of type 2
diabetes, and sodium arsenite which was previously reported to exhibit
insulin-mimetic effects on glucose homeostasis have been reported to
inhibit hepatic gluconeogenesis through SHP-mediated inhibition of
PEPCK and G6Pase gene expression in an AMPK-dependent manner[141,142]. These studies provide a novel molecular mechanism of SHP-
mediated regulation of hepatic glucose homeostasis and indicate that
SHP may be one of the primary targets of AMPK. More recently,
hepatocyte growth factor (HGF), a pleiotropic growth factor, was
identiﬁed as a novel inducer of SHP-mediated suppression of gluconeo-
genesis via activation of the AMPK signaling pathway [28]. HGF and its
family member, macrophage-stimulating factor (MSP), increased up-
stream stimulatory factor-1 (USF-1) DNA binding on the SHP promoter
to activate SHP gene transcription, resulting in suppression of PEPCK and
G6Pase gene expression. This study provides a novel signaling pathway
through HGF/AMPK/USF-1/SHP to inhibit hepatic gluconeogenesis.
Liver glucokinase (LGK), an important hepatic glucokinase, plays
an essential role in sensing and maintaining proper blood glucose
levels. One recent study showed that SHP decreased LGK gene
expression by inhibiting the transcriptional activity of LXRα and
PPARγ via interacting directly with their common heterodimer
partner RXRα to mediate suppression of gluconeogenesis [143].
6.5. SHP in drug metabolism
Avastmajority of drugs aremetabolized in liver, where prodrugs are
frequently converted to active metabolites or drugs are inactivated by
speciﬁc cytochrome P450 (CYP) enzymes. The levels of cytochrome
P450 enzymes control the rate at whichmany drugs are metabolized. It
has become clear that these drugmetabolizing enzymes and drug efﬂux
transporters are directly under the control of tissue-speciﬁc NRs such as
CAR and PXR, which coordinately regulate expression of detoxifying
enzymes and transporters [144]. Originally, SHP had been reported to
bind to and inhibit CAR, a nuclear receptor involved in the induction of
the CYP2 and CYP3 genes in the metabolism of xenobiotics [145].
Further studies showed the induction of CYP2B gene expression by
phenobarbital was mediated by the translocation of CAR from the
cytoplasm to the nucleus, and coexpression of SHP inhibited the
transactivation of the CYP2B genemediated by CAR via either inhibiting
recruitment of other coactivators through the p160 coactivator GRIP1 or
actively recruiting corepressors directly to the CAR/RXR/phenobarbital
responsive unit (PBRU) complex in the CYP2B gene [146].
Like CAR, PXR was initially reported to induce CYP3A gene
transcription following xenobiotic induction by phenobarbital or
rifampicin [147]. Upon activation, PXR controlled elimination of these
compounds by inducing CYP3A4 and Na(+)-independent organic
anion transporter 2 (Oatp2) expression [147–149]. More recently, it
has been shown that PXR is a broad-speciﬁcity sensor that recognizes
a wide variety of synthetic drugs as well as endogenous compounds
such as bile acid precursors [66]. The bile acid mediated induction of
SHP resulted in SHP interacting with bothmurine and human PXR in a
ligand-dependent manner to provoke a repression of PXR-mediated
CYP3A induction. This study revealed an elaborate regulatory cascade,
tightly controlled by SHP, for regulating both the maintenance of bile
acid production and detoxiﬁcation in the liver [66]. A better
understanding of these mechanisms may aid the development of
better agents to decrease serum bile acids in chronic cholestatic liver
diseases such as primary biliary cirrhosis and sclerosing cholangitis
[150,151].
7. SHP in cancer
Nuclear receptors have been implicated in regulating the biology
of a wide variety of cancers, including the initiation and progression of
hepatocellular carcinoma (HCC). In fact, inhibition of SHP in vivo
causes regression of hepatoma [152]. Because of their important
physiologic roles in cancers, nuclear receptors and the critical genes
that they regulate are emerging targets for molecular diagnostic tests
and cancer therapeutics. Accumulating evidence points to the
involvement of SHP in the development of some cancers, particularly
liver cancer and breast cancer.
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Our recent studies demonstrated that SHP has potent tumor-
suppressive activity by inhibiting cellular growth and activating
apoptosis [40,152–154]. Aberrant hypermethylation of promoter
regions in cytosine–guanine dinucleotides (CpG) islands has been
shown to be associated with transcriptional silencing of tumor
suppressor genes in many cancers. We evaluated the methylation
proﬁle and tumor-suppressive function of SHP in the development of
HCC. The expression of SHP was markedly diminished in human HCC
pathologic specimens and cell lines by epigenetic silencing due to SHP
promoter hypermethylation. In vitro methylation decreased SHP
promoter transactivation and nuclear receptor LRH-1 binding which
was reversed by demethylation. Overexpression of SHP also inhibited
human HCC foci formation, arrested HCC tumor growth in xeno-
grafted nude mice, and increased the sensitivity of HCC cells to
apoptotic stimuli. Further analysis of a total of 19 normal human liver
and 57 HCC specimens showed that down-regulation of SHP gene
expression may be a common denominator in HCC [147].
Study of SHP−/−mice provided additional evidence that SHP has a
biological tumor suppressor function by negatively regulating cellular
growth. SHP−/− mice 12–15 months of age developed spontaneous
hepatocellular carcinomas, which were found to be strongly associ-
ated with enhanced hepatocyte proliferation and increased cyclin D1
expression. In contrast, overexpressing SHP in hepatocytes of SHP-
transgenic mice reversed this effect. Embryonic ﬁbroblasts lacking
SHP showed enhanced proliferation and produced increased cyclin D1
messenger RNA and protein, and SHP was shown to be a direct
negative regulator of cyclin D1 gene transcription. In agreement with
this, the immortal SHP−/− ﬁbroblasts displayed characteristics of
malignant transformed cells and formed tumors in nude mice [152].
In addition to suppressing the transcription of a critical cell pro-
liferating gene, SHP can also activate cell death. Apoptosis is a distinct
form of programmed cell death that is best deﬁned morphologically by
nuclear and cell fragmentation. Apoptosis plays a major role in liver
disease, and altered regulation of apoptosis has been shown to be
associatedwith the pathogenesis of HCC and dysplasia in the liver [155].
Our recent studies showed that at least twomechanisms are involved in
the activation of apoptosis and inhibition of tumor growth by SHP. One
mechanism is that inhibition of ERRγ by SHP leads to decreased YY1
expression and the de-repression of YY1 on AP1 activity, which in turn
results in the activation of miR-206 and inhibition of notch3 signaling
[74,154]. Expression of miR-206 markedly induced apoptotic cell death
and blocked the anti-apoptotic activity of Notch3. In addition, ectopic
expression of miR-206 inhibited HeLa cell migration and focus
formation. Therefore,we identiﬁedmiR-206asa pro-apoptotic activator
of cell death, which was associated with its inhibition of notch3
signaling and tumor formation [154].
More recently, we reported a novel cytoplasmic function of SHP
through its regulation of mitochondrial induced apoptosis. SHP acted
as a pivotal cell death receptor that targets mitochondria by binding
Bcl-2, disrupting the Bcl-2/Bid interaction, and inducing cytochrome c
release. The apoptosis inducer AHPN acted by increasing SHP gene
expression and promoting the translocation of SHP from the nucleus
to the mitochondria. Furthermore, induction of apoptosis by activa-
tion of SHP inhibited peritoneal pancreatic tumor growth, suggesting
this may be a mechanism functioning in a variety of cancers [40].
7.2. SHP in breast cancer
Breast cancer is the most common diagnosed cancer of women in
the Western world and second only to lung cancer in mortality rate.
Estrogen is a classical etiological factor for breast cancer and exerts its
biological function via ERα and ERβ in a ligand-dependent manner.
Approximately 70% of breast cancers are ER positive, and adjuvant
anti-estrogen therapy plays an important role in treatment. Previousstudies have reported links between SHP and estrogen signaling, such
as the direct interaction of SHPwith ERs [156], inhibition ER-mediated
transcriptional activation by SHP [43] and ER-dependent transcrip-
tional regulation of SHP in a feedback loop [23]. In postmenopausal
women with breast cancer the source of estrogen driving tumor
growth is produced locally within the tumor and in the surrounding
adipose tissue and is due to activity of aromatase CYP19 [157]. In
further support of this hypothesis, overexpression of aromatase in
adipose tissue contributes to development and progression of breast
cancer. Clinical trials have shown that aromatase inhibitors are
superior to tamoxifen as a ﬁrst line treatment of advanced disease in
postmenopausal women [158]. The fact that SHP enhances the
transcriptional activity of PPARγ in adipose tissue via an atypical
interaction with the DNA-binding domain and hinge region of PPARγ
[7] and ligands for PPARγ are very effective inhibitors of aromatase
expression in adipose stromal cells [159] suggested that SHP might
exert an inhibitory effect on aromatase expression. Indeed, SHP was
shown to inhibit aromatase expression and estrogen production in
breast preadipocytes by preventing LRH-1 transactivation on aroma-
tase promoter II [160]. These studies suggest that SHP inhibits
estrogen action at multiple levels and induction of SHP expression
or activity in breast would be relatively speciﬁc for inhibiting estrogen
signaling in breast cancer. Recently, the FXR agonist GW4064 was
found to up-regulate SHP expression, inhibit aromatase activation and
induce breast carcinoma cell line MCF-7 and MDA-MB-468 apoptosis
[161]. It is, therefore, tempting to speculate that this FXR-SHP-LRH-1
pathway is functionally active in breast cancer and may represent a
therapeutic approach to repress proliferation and to induce apoptosis
in breast cancer treatment.
7.3. SHP in other cancers
Data mining of a microarray database http://www.genecards.org
showed that SHP was down-regulated in many cancers, including
adrenal cortex, cerebellum, kidney, skin, and thyroid, suggesting that
SHP may function as a common tumor suppressor. A more recent
study showed that SHP decreased glioma-associated oncogene
homologue (Gli) target gene expression by repressing the transcrip-
tional activity of Gli [162]. Gli was originally identiﬁed as an ampliﬁed
gene in gliomas, and acted as a terminal effector of the Hedgehog
signaling pathway in cell proliferation and anti-apoptosis tumorigen-
esis. SHP was shown to inhibit transcriptional activity and nuclear
localization of Gli1 via direct protein interaction. These ﬁndings
provide further evidence for a possible link between anti-tumor
functions of SHP and the role of SHP as an inhibitory regulator of
Hedgehog/Gli signaling pathway.
8. Conclusion and perspective
Since its discovery in 1996, SHP has been shown to interact with a
wide variety of transcription factors, including nuclear receptors and
nonnuclear receptor transcription factors, which regulate the expres-
sion of many target genes in a tissue-speciﬁc manner. This wide variety
of SHP-interacting partners is indicative of its regulatory role in many
cellular and physiological pathways, thereby establishing its role as a
critical transcriptional coregulator in metabolic processes. The fact that
SHP regulates bile acid synthesis, lipid, cholesterol, and glucose
metabolism provide a potential means to develop SHP targeted
therapeutics for at least severalmetabolic diseases. Of particular interest
is the observation that the loss of SHP function prevents dyslipidemia,
fatty liver and insulin resistance caused by LDLR or leptin deﬁciency.
These observations raise the possibility of developing synthetic SHP
antagonists to selectively inhibit SHP activity in hepatocytes and
adipocytes as therapeutics for fatty liver, hypercholesterolemia and
obesity. Moreover, SHP plays a preventive role in liver ﬁbrosis providing
a rational to develop SHP agonists as antiﬁbrotic therapeutics. Since
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vitro systems, additional in vivo studies are needed. In this context, it is
also important to keep in mind that possible species differences might
exist with regard to SHP expression, regulation and function. Regarding
the pharmacological modulation of SHP activity, the protein contains a
conserved ligand-binding domain suggesting the possibility that its
activity may be regulated by natural or synthetic ligands. Although no
array of ligands has been identiﬁed to date, several ligands have been
identiﬁed [37]. An important topic of future studies will be to deﬁne the
structure of the ligand-binding domain of SHP to aid the identiﬁcation
and synthesis of activators and inhibitors of SHP.
The new ﬁnding about the cytoplasmic function of SHP through its
regulation of mitochondrial induced apoptosis, which is mediated by
its subcellular localization, indicates that the subcellular localization
of SHP protein has a different biological function than its original
nuclear receptor role. In view of these different functions, studies of
post-translational modiﬁcations of the SHP protein such as acetyla-
tion, methylation, and phosphorylation are essential topics of future
studies. Although a role for SHP stability has been identiﬁed in bile
acid signaling pathways, it will be interesting to see if SHP protein
stability is critical in regulating other pathways such as lipid and
glucose metabolism.
Besides its metabolic regulatory functions, studies by our and other
groups provide strong evidence that SHP plays a critical role in the
development of cancer, particularly in liver and breast cancer. Although
this is a new area of investigation, an increased understanding of the
fundamental mechanisms by which SHP regulates cancer progression,
especially its intriguing role in regulating miRNA expression, is of great
importance in applying this knowledge to newdiagnostics, therapeutics
and prevention strategies for cancer. In this context, identiﬁcation of
SHP regulated miRNA oncogenes or anti-oncogenes is of particular
interest.
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